Results for hyperlipidemia translation from English to Maltese

hypokalaemia, hyperlipidemia, hypophosphataemia
livell baxx ta ’ potassju fid- demm, iperlipidemja, ipofosfatimja

uncommon: hypokalaemia, hyperlipidemia, hypophosphataemia rare: ldh increased
mhux komuni ipokalemija, iperlipidemija, ipofosfatemija rari: ldh ogħla

the risk/ benefit should be considered in patients with established hyperlipidemia before initiating an immunosuppressive regimen including
hekk ukoll ir- riskju/ benefiċċju ta ’ terapija ta ’ rapamune għandu jkun evalwat mill- ġdid f’ pazjenti li jbatu minn iperlipidimja refrattorja severa.

the risk/ benefit should be considered in patients with established hyperlipidemia before initiating an immunosuppressive regimen including rapamune.
ir- riskju/ benefiċċju għandu jkun ikkonsidrat f’ pazjenti li jbatu regolarment minn iperlipidimja, qabel jinbeda t- trattament b’ reġimen immunosoppressiv li jinkludi rapamune.

similarly the risk/ benefit of continued rapamune therapy should be re-evaluated in patients with severe refractory hyperlipidemia.
5 fi studji kliniċi, l- amministrazzjoni ta ’ rapamune ma ’ prodotti li jinibixxu hmg- coa reductase u/ jew fibrati kien ittolerat tajjeb.

patients administered rapamune should be monitored for hyperlipidemia using laboratory tests and if hyperlipidemia is detected, subsequent interventions such as diet, exercise, and lipid-lowering agents should be initiated.
pazjenti li jingħataw rapamune għandhom jiġu mmonitorjati għal iperlipidimja permezz ta ’ testijiet tal- laboratorju u jekk tinstab l- iperlipidimja, interventi sussegwenti bħal ma ’ huma d- dieta, l- eżerċizzju, u mediċini li jbaxxu l- lipidi (xaħmijiet) għandhom jinbdew.

in pooled data from the major efficacy trials, the proportion of patients experiencing successful penetration on vardenafil were as follows: psychogenic erectile dysfunction (77-87%), mixed erectile dysfunction (69-83%), organic erectile dysfunction (64-75%), elderly (52-75%), ischaemic heart disease (70-73%), hyperlipidemia (62-73%), chronic pulmonary disease (74-78%), depression (59-69%), and patients concomitantly treated with antihypertensives (62-73%).
tagħrif miġbur mill-provi ewlenin dwar l-effikaċja wera li l-proporzjon ta’ pazjenti li kellhom suċċess fil-penetrazjoni b’vardenafil kien hekk: problemi erettili ta’ natura psikoġenika (77-87%), problemi mħallta ta’ erezzjoni (69-83%), problemi erettili ta’ natura organika (64-75%), anzjani (52-75%), mard iskemiku tal-qalb (70-73%), iperlipidimja (62-73%), mard kroniku tal-pulmun (74-78%), depressjoni (59-69%) u pazjenti li kienu qed jieħdu mediċini kontra il-pressjoni għolja fl-istess ħin (62-73%).